Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy

被引:12
作者
Cavanaugh, SX
Fuller, CD
Kupelian, PA
Reddy, C
Bradshaw, P
Pollock, BH
Fuss, M
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Radiat Oncol, San Antonio, TX USA
[2] Univ Texas, Hlth Sci Ctr, Div Radiol Sci, San Antonio, TX USA
[3] MD Anderson Canc Ctr, Dept Radiat Oncol, Orlando, FL USA
[4] Cleveland Clin Fdn, Dept Radiat Oncol, Cleveland, OH 44195 USA
[5] Univ Texas, Ctr Biostat & Epidemiol, Hlth Sci Ctr, San Antonio, TX 78285 USA
[6] San Antonio Canc Inst, San Antonio, TX USA
关键词
radiotherapy; prognostic; time; threshold; survival;
D O I
10.1038/sj.pcan.4500831
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The specific aim of this analysis was to evaluate the capability of a time and prostate-specific antigen (PSA) threshold model to prognosticate overall survival ( OS) and disease-specific survival (DSS) based on early PSA kinetics after radiotherapy for prostate cancer by retrospective review of outcomes in 918 patients. Crossing below analyzed PSA thresholds at specific defined time points reduced disease-specific death hazard ratios to relative to the cohort above threshold. The time and PSA threshold model demonstrates the ability to prognosticate OS and DSS as early as 3 months post-radiotherapy for prostate cancer.
引用
收藏
页码:353 / 358
页数:6
相关论文
共 27 条
[1]  
[Anonymous], 1997, Int J Radiat Oncol Biol Phys, V37, P1035
[2]  
BAGSHAW MA, 1985, UROLOGY, V25, P17
[3]   Criteria for the validation of surrogate endpoints in randomized experiments [J].
Buyse, M ;
Molenberghs, G .
BIOMETRICS, 1998, 54 (03) :1014-1029
[4]   Prostate-specific antigen and other markers of therapeutic response [J].
Carducci, MA ;
DeWeese, TL ;
Nelson, JB .
UROLOGIC CLINICS OF NORTH AMERICA, 1999, 26 (02) :291-+
[5]   Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy - Prognostic value of a time-and-PSA threshold model [J].
Cavanaugh, SX ;
Kupelian, PA ;
Fuller, CD ;
Reddy, C ;
Bradshaw, P ;
Pollock, BH ;
Fuss, M .
CANCER, 2004, 101 (01) :96-105
[6]   Prostate-specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer [J].
Critz, FA ;
Levinson, K ;
Williams, WH ;
Holladay, D ;
Holladay, C ;
Griffin, V .
UROLOGY, 1997, 49 (05) :668-672
[7]   Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era [J].
D'Amico, AV ;
Cote, K ;
Loffredo, M ;
Renshaw, AA ;
Schultz, D .
JOURNAL OF UROLOGY, 2003, 170 (06) :S42-S46
[8]   Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy [J].
D'Amico, AV ;
Moul, JW ;
Carroll, PR ;
Sun, L ;
Lubeck, D ;
Chen, MH .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (18) :1376-1383
[9]   Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Wu, YH ;
Chen, MH ;
Hurwitz, M ;
Kantoff, PW ;
Tomaszewski, JE ;
Renshaw, AA ;
Wein, A ;
Richie, JP .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (18) :3240-3246
[10]  
Dawson NA, 1999, SEMIN ONCOL, V26, P174